MTOR and cholangiocarcinoma: The enduring presence of hydrogen bonds and hydrophobic interactions in the catalytic pocket indicates that medicarpin may serve as an effective mTOR inhibitor, stabilising the kinase’s inactive conformation and potentially influencing downstream PI3K/AKT/mTOR signalling pathways associated with CCA progression.